Intracerebral hemorrhage (ICH) is a devastating disease, causing high rates of death,
disability, and suffering across the world. For decades, its treatment has been shrouded by …

Abstract Purpose of Review When compared to ischaemic stroke, there have been limited
advances in acute management of intracerebral haemorrhage. Blood pressure control in the …

The mortality rate of acute intracerebral hemorrhage (ICH) can reach up to 40%. Although
the radiomics of ICH have been linked to hematoma expansion and outcomes, no research …

The major advance in stroke research in 2023 was the realisation that intracerebral
haemorrhage is a treatable condition, shown by the results of three pivotal clinical trials. This …

Intracerebral hemorrhage (ICH) is characterized by hematoma development within the
brain's parenchyma, contributing significantly to the burden of stroke. While non-contrast …

Background The implementation of a care bundle might improve functional outcome for
patients with intracerebral hemorrhage (ICH). However, the impact of anti-hypertensive …

Background: Hematoma expansion (HE) following an intracerebral hemorrhage (ICH) is a
modifiable risk factor and a treatment target. We examined the association of HE with …

Background Andexanet is US Food and Drug Administration (FDA) approved for the reversal
of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are …

Stroke affects up to one in five people during their lifetime in some high-income countries,
and up to almost one in two in low-income countries. Globally, it is the second leading cause …

Continued on page 22 who led stroke programs across the country.“The answer I got was
very curious. I said,'We know we're going to reverse blood thinners when someone comes in …